| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director | General Manager - Diagnostics
3 companies
Cole G Bradley is a General Manager - Diagnostics at EXAS, with reported holdings spanning 3 companies. Recent filings cover 0 purchases and 6 sales. Those positions are worth an estimated $1.3M at current prices.
Cole G Bradley's largest disclosed position is in EXAS as General Manager - Diagnostics, worth about $1.3M. The recent filings there lean toward selling, a net 65,372 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Jul 29, 2026 | KNSA Kiniksa Pharmaceuticals International, Plc | Director | Sell | 3,673 | $81.43 | $299,092.39 | -23.9% | |
| Mar 5, 2026 | CSTL Castle Biosciences, Inc. | Director | Sale+OE | 7,403 | $28.47 | $210,727.17 | -27.7% | |
| Feb 19, 2020 | EXAS Exact Sciences Corp | General Manager - Diagnostics | Sale+OE | 27,356 | $100.00 | $2,735,600.00 | -72.9% | |
| Jan 16, 2020 | EXAS Exact Sciences Corp | General Manager - Diagnostics | Sell | 10,000 | $90.30 | $903,000.00 | -53.6% | |
| Nov 21, 2019 | EXAS Exact Sciences Corp | General Manager - Diagnostics | Sell | 28,016 | $80.38 | $2,251,926.08 | -47.5% |